Point Roberts, WA - March 29, 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, reports on advances in Cancer Immunotherapy. Bristol-Myers Squibb Company (NYSE:BMY) announced Friday that the U.S. Food and Drug Administration (FDA) approved YERVOY (ipilimumab) 3 mg/kg for the treatment of patients with unresectable (inoperable) or metastatic melanoma.

Bristol-Myers Squibb Company (NYSE:BMY) hit a 52 week high on Friday.

"The approval of YERVOY illustrates the power of harnessing the patient's own immune system to combat cancer,” stated Jim Joyce, CEO of Aethlon Medical. "With the recent approval of PROVENGE from Dendreon, the cancer immunotherapy era seems to be well underway.

In this regard, we believe that the elimination of particles released by cancers to suppress the immune response would further unlock the benefit of Yervoy, Provenge, and other immunotherapy candidates in the clinical pipeline.” Aethlon Medical recently discovered that it's Hemopurifier®, a dialysis-like device with broad-spectrum capabilities to capture infectious viral pathogens from circulation, also captures tumor-secreted exosomes that cause programmed cell death of the immune cells required to fight cancer” reports James A. Joyce, Chairman, CEO ofAethlon Medical (OTCBB: AEMD).

Dendreon Corporation (NasdaqGS: DNDN ) was the first to receive FDA approval for its

PROVENGE® (sipuleucel-T) immune cell treatment of cancer. According to the company, it is the first autologous cellular immunotherapy AUTOLOGOUS CELLULAR IMMUNOTHERAPYPROVENGE is classified by the FDA as an autologous cellular immunotherapy. It is designed to be an active cellular immunotherapy. Closeto receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. PROVENGE is designed to induce an immune response against prostate cancer.

RecentBristol-Myers Squibb Company (NYSE:BMY) News:

FDA Approves YERVOY™ (ipilimumab) for the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer

First and Only Approved Therapy for Unresectable or Metastatic Melanoma to Demonstrate a Significant Improvement in Overall Survival

First FDA-Approved Therapy for Unresectable or Metastatic Melanoma in More than a Decade

First Approved Cancer Immunotherapy for Melanoma to Target CTLA-4 and First FDA-Approved Compound in the Company's Robust Immuno-Oncology Pipeline Risk Evaluation and Mitigation Strategy Developed with FDA to Support the Safe and Appropriate Use of YERVOY and Help Inform Patients and Providers About Important Safety Risks

PRINCETON, N.J. - (Investorideas.com Newswire) - Bristol-Myers Squibb Company (NYSE:BMY) announced that the U.S. Food and Drug Administration (FDA) approved YERVOY™ (ipilimumab) 3 mg/kg for the treatment of patients with unresectable (inoperable) or metastatic melanoma. YERVOY is the first and only therapy for unresectable or metastatic melanoma to demonstrate a significant improvement in overall survival based on results from a pivotal randomized, double-blind Phase 3 study. Median overall survival was 10 months (95% CI: 8.0-13.8) for YERVOY, 6 months (95% CI: 5.5-8.7) for gp100 and 10 months (95% CI: 8.5-11.5) for YERVOY + gp100, with p-values of 0.0026 (not adjusted for multiple comparisons) for YERVOY and 0.0004 for YERVOY + gp100 vs. gp100, respectively. As published in the New England Journal of Medicine, the Kaplan-Meier estimated survival rate at 1 year was 46% (95% CI: 37.0, 54.1) in the YERVOY arm vs. 25% (95% CI: 18.1, 32.9) in the gp100 arm. The estimated survival rate at 2 years was 24% (95% CI: 16.0, 31.5) in the YERVOY arm vs. 14%2 (95% CI: 8.0, 20.0) in the gp100 arm. YERVOY, which is a recombinant, human monoclonal antibody, is the first FDA-approved cancer immunotherapy that blocks the cytotoxic T- lymphocyte antigen-4 (CTLA-4).

Full News: http://www.investorideas.com/news/2011/main/03281.asp

Biotech/Pharma Sector Snapshot Trading March 28th

Aethlon Medical (OTCBB: AEMD) traded in a range: $0.13 - 0.1380

Bristol-Myers Squibb Company (NYSE: BMY ) Day's Range: $26.94 - $27.38 on over 18 Million shares

Dendreon Corporation (NasdaqGS: DNDN ) closed at $33.96, up $1.01 (3.07%) with further gains in after hours trading.

Contacts:

James A. Joyce Chairman, CEO 858.459.7800 x301 This email address is being protected from spambots. You need JavaScript enabled to view it.

About InvestorIdeas.com:

InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.

Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

Visit the showcase page on Investorideas.com

http://www.investorideas.com/CO/AEMD

Get added to the company's news alerts:

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech,  biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011       

800-665-0411 - This email address is being protected from spambots. You need JavaScript enabled to view it.

Source - Investorideas.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)

Effective March 15, 2011